Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) - Pipeline Review, H1 2016

Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) - Pipeline Review, H1 2016
Published Jun 15, 2016
37 pages — Published Jun 15, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) - Pipeline Review, H1 2016, provides in depth analysis on Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) targeted pipeline therapeutics.

The report provides comprehensive information on the Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3)
- The report reviews Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targete

  
Source:
Document ID
GMDHC0090TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) Overview61
Therapeutics Development73
  Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) Products under Development by Stage of Development71
  Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) Products under Development by Therapy Area81
  Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) Products under Development by Indication91
Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) Pipeline Products Glance101
  Early Stage Products101
Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) Products under Development by Companies112
Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) Products under Development by Universities/Institutes132
Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) Therapeutics Assessment155
  Assessment by Monotherapy/Combination Products151
  Assessment by Mechanism of Action162
  Assessment by Route of Administration181
  Assessment by Molecule Type191
Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) Companies Involved in Therapeutics Development205
  Addex Therapeutics Ltd201
  Domain Therapeutics SA211
  Medgenics, Inc.221
  Prexton Therapeutics SA231
  Taisho Pharmaceutical Holdings Co., Ltd.241
Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) Drug Profiles257
  DT-011088 Drug Profile251
  fasoracetam Drug Profile261
  MGS-0028 Drug Profile271
  Small Molecules to Agonize mGluR3 for Parkinson's Disease Drug Profile281
  Small Molecules to Antagonize mGluR3 for Anxiety and Depression Drug Profile291
  Small Molecules to Modulate mGlu3 Receptor for CNS Disorders Drug Profile301
  VU-0092273 Drug Profile311
Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) Dormant Projects322
Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) Discontinued Products341
Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) Featured News &Press Releases351
  Apr 14, 2014: Domain Therapeutics continues program to alter course of Parkinson s disease with renewed support by The Michael J. Fox Foundation351
Appendix362
  Methodology361
  Coverage361
  Secondary Research361
  Primary Research361
  Expert Panel Validation361
  Contact Us361
  Disclaimer371

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) - Pipeline Review, H1 2016" Jun 15, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Metabotropic-Glutamate-Receptor-3-mGluR3-or-GRM3-or-GPRC1C-or-MGLUR3-Pipeline-Review-H1-2016-2088-15970>
  
APA:
Global Markets Direct - Market Research. (2016). Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) - Pipeline Review, H1 2016 Jun 15, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Metabotropic-Glutamate-Receptor-3-mGluR3-or-GRM3-or-GPRC1C-or-MGLUR3-Pipeline-Review-H1-2016-2088-15970>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.